Focus: Masimo is a publicly traded medical device company (MASI) headquartered in Irvine, CA with 5,001–10,000 employees, specializing in non-invasive patient monitoring technologies including pulse oximetry and vital sign sensors. The company operates at significant scale as an established public entity with $2.0B revenue in FY 2024.
Profile data last refreshed 2h ago · AI intelligence enriched 1w ago
Masimo offers stability and scale in established monitoring technology, but sharp revenue decline and minimal hiring activity warrant careful evaluation of near-term restructuring risk.
Help build intelligence for Masimo
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Masimo's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Based on last 4 crawl cycles
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo